US-based molecular diagnostics company DiaCarta has developed a new test to detect the new emerging Covid-19 variant, Omicron. The new multiplex qPCR-based test named QuantiVirus SARS-CoV-2 Variant Detection is based on DiaCarta’s proprietary XNA technology. It is designed to identify the SARS-CoV-2 virus and then distinguish various mutating variants. The company has secured CE/IVD marking and will commercialise this test globally.
Rheonix has confirmed that its Covid-19 MDx Assay is capable of detecting the emerging Omicron variant. The company said that the RT-PCR assay can also identify other SARS-CoV-2 variants of concern. The Rheonix Covid-19 MDx Assay is designed for the qualitative detection of nucleic acid from SARS-CoV-2 using saliva samples. The test is yet to be approved by the US Food and Drug Administration (FDA). However, the FDA has granted the test emergency use authorization (EUA) for use by authorised laboratories.
Health technology company Detect has said that its PCR-quality, at-home rapid Covid-19 Test recognises the Covid-19 Omicron variant. The company made the announcement following a comprehensive bioinformatics analysis. The test is said to offer results in less than one hour. Recently, Detect’s Covid-19 Test was selected for the National Institutes of Health (NIH) Rapid Acceleration of Diagnostics Initiative (RADxSM) to increase production.